Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

<p><strong>Background:</strong> Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their antiviral activities in patients have not been compared directly. The aim of this ongoing platform trial is to compare different antivir...

Celý popis

Podrobná bibliografie
Hlavní autoři:	Schilling, WHK, Jittamala, P, Watson, JA, Boyd, S, Luvira, V, Siripoon, T, Ngamprasertchai, T, Batty, EM, Cruz, C, Callery, JJ, Singh, S, Saroj, M, Kruabkontho, V, Ngernseng, T, Tanglakmankhong, N, Tubprasert, J, Abdad, MY, Madmanee, W, Kouhathong, J, Suwannasin, K, Pagornrat, W, Piaraksa, N, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Poovorawan, K, Potaporn, M, Srisubat, A, Loharjun, B, Taylor, WRJ, Chotivanich, V, Chotivanich, K, Imwong, M, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Teixeira, MM, Piyaphanee, W, Phumratanaprapin, W, White, NJ
Další autoři:	PLATCOV Collaborative Group
Médium:	Journal article
Jazyk:	English
Vydáno:	Elsevier 2023

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Podobné jednotky